| Everolimus and giant-cell astrocytomas in tuberous sclerosis. | |
| | |
MedLine Citation:
|
PMID: 21306253 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
To the Editor: Krueger et al. (Nov. 4 issue)(1) report on a striking effect of everolimus, an oral inhibitor of the mammalian target of rapamycin (mTOR), on subependymal giant-cell astrocytomas, which are benign tumors composed of large ganglionic astrocytes. These tumors show strong expression of CD98 (the heavy chain of 4F2 cell-surface antigen and fusion regulatory protein 1) and a system L-type amino acid transporter (LAT-1) that induces multinucleated giant-cell formation and is essential for the maintenance of cell volume. Inhibition of the mTOR signaling pathway has been shown to decrease the activity of the system LAT-1,(2) which we speculate . . . |
| | |
Authors:
|
Hiroshi Nawashiro; Nariyoshi Shinomiya |
Related Documents
:
|
9615343 - Biological verification of heavy ion treatment planning. 21437333 - Planar scattering from hierarchical anatase tio(2) nanoplates with variable shells to i... 9560223 - Targeted disruption of p70(s6k) defines its role in protein synthesis and rapamycin sen... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: The New England journal of medicine Volume: 364 ISSN: 1533-4406 ISO Abbreviation: N. Engl. J. Med. Publication Date: 2011 Feb |
Date Detail:
|
Created Date: 2011-02-10 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0255562 Medline TA: N Engl J Med Country: United States |
Other Details:
|
Languages: eng Pagination: 576-7 Citation Subset: AIM; IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Everolimus and giant-cell astrocytomas in tuberous sclerosis.
Next Document: Tiotropium step-up therapy in asthma.